First Time Loading...

Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3

Watchlist Manager
Ouro Fino Saude Animal Participacoes SA Logo
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Watchlist
Price: 20.24 BRL 1.91% Market Closed
Updated: Jun 7, 2024
Section:
 

Relative Value

The Relative Value of one OFSA3 stock under the Base Case scenario is 41.03 BRL. Compared to the current market price of 20.24 BRL, Ouro Fino Saude Animal Participacoes SA is Undervalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OFSA3 Relative Value
Base Case
41.03 BRL
Undervaluation 51%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.1
P/S
P/S
Price to Sales
1.1
vs History
93
vs Industry
68
Median 3Y
1.3
Median 5Y
1.6
Industry
2.4
Forward
1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
4
Median 3Y
10.5
Median 5Y
13.7
Industry
22.4
Forward
10.5
More Details
6.2
P/OCF
P/OCF
Price to OCF
6.2
vs History
93
vs Industry
43
Median 3Y
16.1
Median 5Y
18.7
Industry
16.9
More Details
7.5
P/FCFE
P/FCFE
Price to FCFE
7.5
vs History
65
vs Industry
31
Median 3Y
13.1
Median 5Y
13.7
Industry
22.6
More Details
1.6
P/B
P/B
Price to Book Value
1.6
vs History
95
vs Industry
46
Median 3Y
1.8
Median 5Y
2.2
Industry
2
More Details
1.1
EV/S
EV/S
Enterprise Value to Sales
1.1
vs History
96
vs Industry
69
Median 3Y
1.4
Median 5Y
1.6
Industry
2.5
Forward
0.9
More Details
2.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.4
vs History
96
vs Industry
67
Median 3Y
2.9
Median 5Y
3.3
Industry
5.1
More Details
6.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.5
vs History
96
vs Industry
42
Median 3Y
7.8
Median 5Y
9.1
Industry
13.3
Forward
4.6
More Details
8.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.4
vs History
95
vs Industry
39
Median 3Y
9.5
Median 5Y
10.9
Industry
16.6
Forward
5.6
More Details
6
EV/OCF
EV/OCF
Enterprise Value to OCF
6
vs History
93
vs Industry
44
Median 3Y
18
Median 5Y
19.1
Industry
15.7
More Details
8.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8.4
vs History
74
vs Industry
31
Median 3Y
9
Median 5Y
19.8
Industry
17.7
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
93
vs Industry
50
Median 3Y
1.4
Median 5Y
1.6
Industry
1.9
More Details

Multiples Across Competitors

OFSA3 Competitors Multiples
Ouro Fino Saude Animal Participacoes SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BR
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
1.1B BRL 1.1 -32.4 6.5 8.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
808.2B USD 22.5 131.7 64.3 73.2
DK
Novo Nordisk A/S
CSE:NOVO B
4.4T DKK 18 49.1 36.6 40.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
355.6B USD 4.2 9.2 11.4 14.9
US
Merck & Co Inc
NYSE:MRK
330.9B USD 5.4 143.5 35.7 58.3
UK
AstraZeneca PLC
LSE:AZN
194.6B GBP 5.2 39.3 175.3 279.6
CH
Roche Holding AG
SIX:ROG
193.3B CHF 3.3 16.8 9.5 11.3
CH
Novartis AG
SIX:NOVN
186.1B CHF 3.6 11.9 9.1 13.2
US
Pfizer Inc
NYSE:PFE
163.4B USD 3 -528.6 12.8 20.7
P/E Multiple
Earnings Growth
BR
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Average P/E: 57.4
Negative Multiple: -32.4 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
131.7
364%
DK
Novo Nordisk A/S
CSE:NOVO B
49.1
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.2
-21%
US
Merck & Co Inc
NYSE:MRK
143.5
7 598%
UK
AstraZeneca PLC
LSE:AZN
39.3
175%
CH
Roche Holding AG
SIX:ROG
16.8
28%
CH
Novartis AG
SIX:NOVN
11.9
17%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -528.6
683%

See Also

Summary
OFSA3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
OFSA3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OFSA3 stock valuation using valuation multiples.
Wall Street Estimates
OFSA3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OFSA3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 144,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.